Ganirelix acetate
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diminished Ovarian Reserve
Conditions
Diminished Ovarian Reserve, Infertility, In Vitro Fertilization
Trial Timeline
May 1, 2012 → Sep 1, 2014
NCT ID
NCT01614067About Ganirelix acetate
Ganirelix acetate is a approved stage product being developed by Merck for Diminished Ovarian Reserve. The current trial status is terminated. This product is registered under clinical trial identifier NCT01614067. Target conditions include Diminished Ovarian Reserve, Infertility, In Vitro Fertilization.
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01614067 | Approved | Terminated |